Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm
Allogeneics Still Waiting For Breakthrough
Executive Summary
Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors.
You may also be interested in...
Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.
Six Questions For GSK Ahead Of Crucial Investor Day
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.